Steve Brozak
Stock Analyst at WBB Securities
(2.81)
# 1,958
Out of 5,084 analysts
14
Total ratings
42.86%
Success rate
50.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $10.98 | +309.84% | 3 | Oct 15, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Strong Buy | $123 → $199 | $220.51 | -9.75% | 5 | Oct 9, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.97 | +204.57% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.42 | +782.15% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.18 | +1,355,832.20% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $10.98
Upside: +309.84%
Cidara Therapeutics
Oct 9, 2025
Maintains: Strong Buy
Price Target: $123 → $199
Current: $220.51
Upside: -9.75%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.97
Upside: +204.57%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.42
Upside: +782.15%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.18
Upside: +1,355,832.20%